Brief: Unity Biotechnology Announces 48-Week Results From Phase 2 Envision Study Of Ubx1325 In Patients With Wet Age-Related Macular Degeneration
27/09/2023 12:19
UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY ANNOUNCES 48-WEEK RESULTS FROM PHASE 2
ENVISION STUDY OF UBX1325 IN PATIENTS WITH WET AGE-RELATED
MACULAR DEGENERATION
* UNITY BIOTECHNOLOGY INC - UBX1325 WAS WELL TOLERATED IN
BOTH
MONOTHERAPY AND COMBINATION ARMS
* UNITY BIOTECHNOLOGY INC - INITIATED A PHASE 2B STUDY IN
PATIENTS
WITH DIABETIC MACULAR EDEMA & EXPECTS TO RANDOMIZE FIRST PATIENT
IN THAT STUDY IN Q4
Source text for Eikon: ID:nGNXfWnTg
Further company coverage: UBX.O
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force